klf

APTO-253 (LOR-253) inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through the induction of the KLF4 tumor suppressor.

ML264 (CID-51003603) is a selective kruppel-like factor 5 (KLF5) inhibitor, which potently Inhibits growth of Colorectal Cancer.

CKLF1-C27, a C-terminal peptide of CKLF1, effectively binds to and activates the CCR4 receptor, triggering the ERK1 2 pathway. Competing with CKLF1 for the CCR4 receptor, it neutralizes CKLF1's cellular effects. Additionally, CKLF1-C27 significantly promotes the proliferation of HUVECs and holds promise for psoriasis research [1].

CKLF1-C27 TFA, a C-terminal peptide of CKLF1, binds to the CCR4 receptor and activates the ERK1 2 pathway. It can abrogate the effect of CKLF1 on cells by competing for the CCR4 receptor and shows significant effects on promoting proliferation in HUVECs. CKLF1-C27 TFA has the potential for psoriasis research [1].

CKLF1-C19, the C-terminal peptide of human chemokine-like factor 1 (CKLF1), interacts with CCR4 and inhibits chemotaxis induced by CKLF1 and CCL17. It also suppresses allergic lung inflammation by inhibiting chemotaxis mediated by CCR3 and CCR4 [1].

2-(4-methoxyphenyl)-2-oxoethyl 2-hydroxy-5-methylbenzoate is a pro-neurotropic drug used to enhance cognitive function by increasing the synthesis and release of acetylcholine in the brain as well as by inhibiting the breakdown of acetylcholine by acetylcholinesterase.

CID 5951923 is an inhibitor of KLF5 transcription factor with an IC50 of 603 nM.

Obeticholic Acid (6-ECDCA, INT-747) is a high-affinity, semisynthetic, bile acid-derived FXR agonist with an EC50 of 99 nM and is able to upregulate IκB-α, KLF-2, and KLF-4 expression. Obeticholic Acid (6-ECDCA, INT-747) also shows potential for treating hepatic steatosis, inflammation, and fibrosis while increasing insulin sensitivity.

SR15006 is Krüppel-like factor 5 (KLF5) inhibitor (IC50 = 41.6 nM).